Preclinical success against Alzheimer's disease with an old drug

New England Journal of Medicine

Volumn 367, Issue 6, 2012, Pages 570-572

  LaFerla, Frank M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BEXAROTENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRESENILIN 1; PRESENILIN 2; RETINOID X RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN GENE; APOLIPOPROTEIN E GENE; APOLIPOPROTEIN E2 GENE; APOLIPOPROTEIN E3 GENE; APOLIPOPROTEIN E4 GENE; ARTICLE; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG MECHANISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRESENILIN 1 GENE; PRESENILIN 2 GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR;

EID: 84864693858     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1204890     Document Type: Article

References (4)

1. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-6.
2. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44. [Erratum, N Engl J Med 2011;364:588.]
3. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681-93. (Pubitemid 351778466)
4. Lowenthal J, Hull SC, Pearson SD. The ethics of early evidence - preparing for a possible breakthrough in Alzheimer's disease. N Engl J Med 2012;367:488-90.